T he cone snail, Conus magus, waits among corals for a small fish to swim into striking distance. A carnivorous predator with a spiral-shaped shell, the blind cone snail tracks its prey by smell. When a fish swims into close range, C. magus extends its flexible, tube-like proboscis from its siphonal canal, probing the animal as if measuring its dimensions.
Then, like a hunter with a blowgun, the cone snail shoots a harpoon-shaped tooth laced with venom through its proboscis into its prey. The venom's first dose causes convulsions. Impaled on the cone snail's barbed tooth, the fish flops wildly. The second dose causes paralysis, and the fish stiffens, its fins spasming. Now, the immobilized prey can be consumed without a struggle. Later, the cone snail will regurgitate the fish's bones and scales like a "cat coughing up a hair ball, " says Baldomero M. Olivera, a biologist at the University of Utah and a leading researcher in components of cone snail venom.
Olivera and other researchers find that, despite its toxicity in nature, the venom of cone snails and other animals contains components that, when isolated and synthesized, may be transformed from poison into therapies for humans. Over the past decade, increasingly affordable, powerful, and sophisticated technologies have allowed scientists to mine potentially valuable venom peptides and proteins from even very small animals.
Six drugs on the market in the United States are derived from or inspired by venom toxins or venom components. Many other drugs have reached clinical trials, but the vast majority have been dropped before gaining approval by the US Food and Drug Administration (FDA), usually because the drugs proved clinically ineffective. (The same problem confounds drug design and development in general. A survey by Michael Hay and colleagues in the 9 January 2014 Nature Biotechnology showed that between 2003 and 2007, only 10 percent of 4000 compounds in phase I trials reached FDA approval, and most failures were due to clinical ineffectiveness.) Still, the number of approved venombased drugs is likely to increase, some scientists say. Researchers can now tease out peptides from the venoms of many more animals around the world. As many as 100,000 species (a conservative estimate) of fish, snails, snakes, scorpions, spiders, leeches, bees, lizards, and other animals are venomous, and each venom may contain many compounds to explore.
Today's pipeline of venom-derived drugs, moreover, is larger than ever. Several venom-based compounds are in clinical trials, and others are in preclinical development. "We have made progress in being able to pull out compounds from venom more efficiently and much faster, " says Olivera. But locating a potentially valuable toxin is just the beginning of a painstaking process. "Once you discover the compounds, " he says, "you still have to assess individually how effective these compounds can be for biomedical applications, and those are the longest steps. " In the 1990s, Olivera and his team isolated and purified a C. magus toxin that blocks certain pain signals in animal models. Researchers synthesized this toxin to create ziconotide (brand name: Prialt), which was approved by the FDA in 2004. Ziconotide is a nonnarcotic analgesic that is used to treat extreme pain when other medicines cannot be tolerated or fail to provide relief.
"Evolution makes a venom as selective and powerful as possible to be as effective as possible, " explains Olivera. "When a venom compound is hitting a particular target, that is what it evolved to do, and generally, it won't hit any other target with the same potency or affinity. A selective compound is more desirable as a therapeutic because it is likely to cause fewer side effects. "
Ziconotide was a breakthrough drug. It was the first venom-inspired painkiller, and, unlike morphine, it is nonaddictive. Some scientists predicted that many more new venominspired drugs would successfully treat diseases and disorders, including the pain caused by cancer, diabetes, multiple sclerosis, and HIV/AIDS. Yet progress has been slow.
Why venom?
Venom is a fluid concocted by an animal and injected into another animal by fang, barb, spine, or stinger. Each venom is a complex mixture that contains dozens or even hundreds of toxins-proteins and peptides-that can be delivered in a single dose or in multiple doses.
Most venom toxins have evolved to attack a single molecule in an animal's nervous system or cardiovascular system. Some toxins kill by clotting blood and stopping the heart, whereas others prevent clotting and trigger a bleed that kills. Some toxins rupture cell walls at the point of injection, which leads to tissues dying. The tissues can eventually become gangrenous and rot away. Many other venom toxins attack the target animal's nervous system. For instance, each of the 200 peptides in C. magus venom fits perfectly-like a key into a lock-into a specific nerve receptor and stops ion signals between cells. As a result, crucial messages are blocked among nerves, muscles, and organs, causing various discrete reactions in the prey's nervous system. In animal models, for instance, C. magus toxins cause the trembling or loss of control of a target animal's back legs-or lead to the agitated climbing of cages, limb paralysis, or convulsions.
A peptide that attacks the nervous system is like a "very, very strong gum, " says Todd Castoe, a genomicist at the University of Texas at Arlington. "The natural neurotransmitter can't compete with such a strong binding to the receptor; no signals can go through. The peptides have evolved to have extremely high binding affinity to things like pain receptors. If we can use these chemicals, maybe slightly tweak their activity, they should provide really potent pain drugs. "
The pharmacological toolbox Most venoms are used for capturing prey, and a smaller fraction are used for protection against predators or competitors. "Venoms have evolved to knock down prey or predators fast, " says Irina Vetter, a neuropharmacologist at the University of Queensland in Brisbane, Australia. "Some ant venoms have the molecular equivalent of a sledgehammer. They are not refined. They punch a hole in the cell membrane and completely mess up the signaling and allow an influx of ions that cause extreme pain. But many other venoms are exquisitely precise and potent. Nature supplies us with an almost ideal pharmacological toolbox to learn how pain works. Venoms target all of the essential components of nerve signaling, and that's important [in order] to understand how the pain is transmitted in the body and how it can be stopped. "
Each venom molecule has a role to play in the venomous animal's fight for survival. "A venom is like a cluster bomb, " says Mände Holford, a chemical marine biologist at Hunter College, the An estimated 100,000 species of fish, snails, snakes, scorpions, leeches, bees, lizards, spiders, and other animals are venomous-including the infamous black widow spider. Photograph: Paul Sapiano.
City University of New York, and the American Museum of Natural History. "When a cluster bomb explodes, it breaks up into all these little exploding bombs that cause more destruction. When venom enters the system of its prey, it breaks up into little bombs that are quite specific in what target they are going after. " A venom shares three crucial elements with effective medicines, says Holford. "It has to be fast acting, it has to be very specific, and it has to act in a way that will allow the predator to have a meal. If those three things do not occur, you will not have a predator survive for long. An effective drug has those same elements: It must [be] very fast acting, [be] very specific, and it's got to do what you need it do. When you have a headache, you don't want something that will work in five hours; you want to hit it right away and not have a side effect. "
Only 10 years ago, scientists faced a number of practical limitations when choosing suitable venomous animals to study. Large volumes of a venom were required to purify its components. Many venomous organisms, though, are small and produce small quantities of venom. Some animals produce venom only when they need it. But even tiny, obscure, and hard-tocollect venomous organisms can hold dozens of toxins that could be storehouses of potential pharmaceuticals.
Large species, such as snakes, were the most important subjects for biomedical study for many years. Venom research gained momentum in the 1950s and 1960s in countries searching for antivenoms for bites by dangerous snakes. Scientists, for instance, learned that the bite of the Brazilian viper (Bothrops jararaca) causes a catastrophic drop in the victim's blood pressure. From this research effort, Bristol-Myers Squibb chemists synthesized a hypertension drug, captopril, an angiotensin-converting-enzyme (ACE) inhibitor that was approved by the FDA in 1981 and became a blockbuster drug. In 1998, the FDA approved a blood thinner named eptifibatide, modeled on a rattlesnake peptide that affects blood clotting and is used to prevent heart attacks and other conditions. A similar drug called tirofiban, which FDA approved a year later, was inspired by a protein from vipers. Another drug, exenatide, which was synthesized from a compound in the saliva of the Gila monster (Heloderma suspectum), which inhabits US Southwestern deserts, has become a major treatment for type-2 diabetes.
Scientists are now using combinations of complex tools-genomics (DNA), transcriptomics (RNA), and proteomics with mass spectronomy (proteins)-to understand the structures and functions of the most bioactive proteins from the tissues of venom glands. Once a protein has been sequenced, it can be produced artificially in large volumes by cloning it and growing it in bacteria or yeast or by making it by chemical synthesis. These technologies have become less expensive, more accurate, and more powerful in recent years. "In the past, we had to focus on animals that were big and easy to get and animals that you could milk and get a lot of venom from, " says Holford, who studies species of terebrids-very small venomous marine snails-that inhabit tropical waters around the world. "You don't have to be limited anymore because you don't need as much venom material . . . Terebrids are tiny compared to snakes and produce a minimal amount of venom. Now we need venom material from only one snail instead of 80. "
The hunt for compounds With so many choices of venomous animals, researchers have a challenging job deciding where to begin looking for potential medicinal compounds.
"My view is you need an evolutionary guided search strategy," says Bryan Fry, a herpetologist and venom hunter at the University of Queensland. "By identifying the biodiversity hotspots, you can find where venom is varying the most. That is where you are going to find the most unusual toxins. The more unusual a toxin is, the better are your chances to find something novel and useful as a human medicine."
Fry travels to wild places to gather venom in such hotspots. "If you purchase venom, you don't have control of what is in the vial, and you are relying on someone else's identification of the animal to get the species right. And if you buy it, you might not have the geography right, " he says. Knowing an animal's specific geography is essential to understanding its venom. "Even within a single species, a venom can vary dramatically across its geographical range. "
Each venom is a powerful cocktail of toxins that evolved for an ecological purpose, and it is constantly changing. When a prey species evolves a resistance to a venom, the predator's venom must evolve its toxin in the chemical arms race.
Each venom toxin is encoded by a gene. These genes may be more likely than other kinds of genes to create a duplicate, researchers have found. The original gene is not harmed or altered by this duplication, but the copy gene becomes something of a wild card. Evolution can now act on this wildcard gene in new ways. The original gene, however, stays true to its old ordinary "household" function.
The wild-card gene can undergo mutations that change its function.
Herpetologist Bryan Fry travels to biodiversity hotspots in search of rare toxins, such as the venom found in this Antarctic giant octopus.
"The duplicated gene can be free from selection to wander around, accrue mutations, and become a toxin, " says Castoe.
In highly venomous snakes, venom genes have duplicated many times, and the duplicates over time eventually mutate to become highly potent toxins. This process has led to highly complex venom cocktails that contain many different types of toxins.
The study of venom evolution and the search for novel toxins have become increasingly intertwined. Now, some scientists are looking deeper into evolutionary history. One question is how venom genes evolved from ordinary household genes many millions of years ago.
In the 1 January 2015 issue of Molecular Biology and Evolution, Castoe and his colleagues report on their study of the Burmese python (Python molurus bivittatus), which is not considered venomous. Twentyfour so-called "toxic" gene families, each associated with venom, are shared by pythons and venomous cobras, rattlesnakes, and Gila monsters. The researchers found these toxic gene families not only in python oral glands but also in other tissues in the python's body, including tissue from its brain, liver, stomach, and several other organs.
"Venoms evolved from proteins that had normal household cellular function, " says Castoe. "We know what happens in highly venomous snakes: Genes duplicate; they become venomous and are expressed in the mouth. But the python shows us lots of evidence for what happens before that. "
The research team devised a model of three steps for venom evolution: First, potentially venomous genes are expressed in low but consistent ways throughout the body, including an oral gland by default. Then, through natural selection, tissues in the mouth express those genes in higher levels than in other parts of the body. Finally, as the venom in the gland evolves to become more toxic, the expression of those genes in other tissues of the body is reduced to avoid exposure to toxins.
"If you have a new mouth gland or a little extra pocket occurs during random development in the mouth, " says Castoe, "chances are these genes are going to be there at low levels, just by random chance. That provides a perfect starting material for those genes that can become venoms and then continue the process of becoming venoms. When it's beneficial, evolution can very easily and subtly start increasing and increasing and increasing how much is made in the gland or tissue by duplication. "
Some animals under intense evolutionary pressure duplicate their venom genes at an exceptionally fast rate, allowing many more chances for new duplicated genes to evolve and encode new toxins. Cone snails, for instance, duplicate their venom genes at the fastest rate ever found in the animal kingdom, according to an article by Dan Chang and colleagues in the 15 February 2012 issue of Molecular Biology and Evolution.
"Cone snails have been under a lot of evolutionary pressure to be able to capture prey and survive on a coral reef, " says Michael McIntosh, a biologist at the University of Utah who collaborates with Olivera. "The prey they are trying to hunt are often a lot more agile or well protected, so they have to make the most out of their venom. There is a lot of pressure on them to come up with something that is potent and acts quickly. The diversity of cone snail prey requires them to create pretty diverse venoms. A snake will hunt small mammals or birds. But cone snails are hunting things from The Burmese python (Python molurus bivittatus), not considered venomous, has toxic gene families throughout its body, providing clues to venom's evolution.
This specimen is on a heat map, revealing gene expression data for the python's heart, before and after consuming a large meal, which causes the heart to grow substantially. Photograph: Todd Castoe.
five different phyla. Since there are so many species of cone snails and there are so many types of prey, they are mini-factories for producing libraries of compounds that are designed for their purposes but also have oftentimes unique actions on mammalian receptors and ion channels. "
Limitations of venom-based drugs
Despite optimism about venom-based drugs, peptides and proteins often have crucial limitations in biomedical applications. First, peptides and proteins are broken down by enzymes in the human stomach and cannot be taken orally. Moreover, venom compounds are so large that they will not pass through the blood-brain barrier. Small synthetic molecules, by contrast, pass this barrier more easily. Ziconotide must be administrated by spinal tap, an invasive procedure, and works mostly in the central nervous system, unlike morphine, which works more easily by injection into the bloodstream. Holford has been looking for another pathway to administer the drug. In the 3 August 2015 issue of Scientific Reports, Holford and a colleague describe a new method that they have developed in a laboratory model of the brain barrier: "We get the peptides expressed inside viral nanocontainers and shuttle them across the blood-brain barrier as an alternative route. " Venom-based drugs often lose their effectiveness in the transition from animal models to human patients. When a venom compound has been found effective in the rat model or the mouse model, it is tested on larger animal models. If it still looks effective, clinical investigators might try it on patients with severe pain, for instance. But venom components often lose their potency and accuracy when used as medicine in the human body. "The compound might fall in potency to the point that it is not selective at all and it is hitting other targets, " says Olivera. "But the failure rate [in clinical trials] for venom compounds because of unexpected side effects is still much lower than the failure rate of synthetic compounds in general, " he adds.
New drugs also have to compete with older medicines that are effective, already accepted by physicians, and often cheaper because they might be off patent. Regulatory hurdles for drug approvals, meanwhile, are getting higher, which makes the successful development of new compounds more difficult and costly.
However, with millions of diverse, powerful, and targeted venom chemicals, along with improved technologies, the hunt for beneficial uses for venom will continue. Success will depend in part on deciphering venom's evolution. "We have to know what is happening evolutionarily if we are going to find medicines that will help us in our fight against disorders and disease, " says Holford. "We are not smart enough on our own to think up all of the things that nature has been doing for millions and millions of years. " American Museum of Natural History.
